Adverse Event Reporting
| VAERS ID | 907101 |
|---|---|
| Gender | Female |
| Age | 41 |
| StateCode | ME |
| Pharmaceutical Company | PFIZER\BIONTECH |
| Lot Number | EL1284 |
| Number of vaccinations | 1 |
| Vaccinated | 2020-12-22 |
| Onset | 2020-12-22 |
| Condition | Hospitalized Life Threatening Recovered |
Symptoms
- Hyperhidrosis
- Nausea
- Palpitations
- Cough
- Chest X-ray
- Speech disorder
Current Illness
had been feeling slightly under the weather two weeks ago; no current asthma exacerbation, but has very labile asthma
Preexisting Conditions
Sleep apnea on CPAP eosinophilic asthma on multiple controller meds environmental allergies obesity
Other Medications
SIngulair, advair, Duonebs, dupixent, albuterol, zyrtec, chlorpheniramine; wellbutrin, Sertraline;
Previous Vaccinations
Allergies
Anaphylaxis hx to NSAIDS; hs of environmental allergies, and reaction to latex
Laboratory Data
12/22/20 - CXR ordered - results not currently available
Write-up
patient felt slightly nauseated at 10 minutes after injection, then developed slight sweating; BP 160/81; 83 at 5:45 and then 158/87 with HR 82 at 5: 52 pm.
Her lungs were clear, she was speaking in full sentences and was denying any chest pressure, her usual sense of asthma exacerbation.
At 6:05 it was 164/83 with HR 79 and patient developed a dry cough; we decided to have her wait just a bit longer, then cough worsened, so at 6:25, decision was made to have patient seen in ER for further assessment, and en route in wheelchair to ER the dry cough became persistent, spasmodic and patient was unable to speak.
Epi-Pen was injected in right mid thigh, and patient transported to ED urgent eval.
She noted immediate palpitations, and slight improvement of breahting, was able to speak in four word sentences.
On arrival to the ED, patient was administered Duonebs, Albuterol neb, IV Benedryl, IV Solumedrol; CXR was obtained, with results pending.
Patient was sent to observation for ongoing monitoring and assessment of breathing.
at 6:30 PM in the ER, she